Drug, across the briefings

Contusugene Ladenovec across 47 cancers

Contusugene Ladenovec appears in 47 of the briefings; no FDA label names any of them.

DiseaseFDA labelOpen Targets stage, on which geneTrialsActive
Acute lymphoblastic leukemiaphase 3 on TP53——
Acute myeloid leukemiaphase 3 on TP53——
Anal cancerphase 3 on TP53——
Basal cell carcinomaphase 3 on TP53——
Bladder cancerphase 3 on TP5310
Breast cancerphase 3 on TP5360
Burkitt lymphomaphase 3 on TP53——
Cervical cancerphase 3 on TP5310
Cholangiocarcinomaphase 3 on TP53——
Chronic lymphocytic leukemiaphase 3 on TP53——
Chronic myeloid leukemiaphase 3 on TP53——
Colorectal cancerphase 3 on TP53——
Cutaneous squamous cell carcinomaphase 3 on TP53——
Diffuse large B-cell lymphomaphase 3 on TP53——
Endometrial cancerphase 3 on TP53——
Esophageal cancerphase 3 on TP5310
Ewing sarcomaphase 3 on TP53——
Gallbladder cancerphase 3 on TP53——
Gastric cancerphase 3 on TP5310
Gastrointestinal stromal tumourphase 3 on TP53——
Glioblastomaphase 3 on TP5320
Head and neck cancerphase 3 on TP5350
Hepatocellular carcinomaphase 3 on TP5320
Lower-grade gliomaphase 3 on TP53——
Lung cancerphase 3 on TP5361
Mantle cell lymphomaphase 3 on TP53——
Marginal zone lymphomaphase 3 on TP53——
Medulloblastomaphase 3 on TP53——
Merkel cell carcinomaphase 3 on TP5310
Mesotheliomaphase 3 on TP53——
Multiple myelomaphase 3 on TP53——
Myelodysplastic syndromesphase 3 on TP53——
Myeloproliferative neoplasmsphase 3 on TP53——
Nasopharyngeal carcinomaphase 3 on TP53——
Osteosarcomaphase 3 on TP53——
Ovarian cancerphase 3 on TP5340
Pancreatic cancerphase 3 on TP53——
Prostate cancerphase 3 on TP53——
Rhabdomyosarcomaphase 3 on TP53——
Small cell lung cancerphase 3 on TP5330
Small intestine cancerphase 3 on TP53——
Soft tissue sarcomaphase 3 on TP53——
Testicular cancerphase 3 on TP53——
Thyroid cancerphase 3 on TP53——
Vulvar cancerphase 3 on TP53——
Waldenström macroglobulinaemiaphase 3 on TP53——
Wilms tumourphase 3 on TP53——

The label column is the briefing's openFDA stage: a label whose Indications and Usage names the disease. The Open Targets column is the furthest clinical stage recorded for the drug against any gene on that briefing's target list, in any indication. Trials are ClinicalTrials.gov interventional studies naming the drug and the disease, from the briefing's trials stage; a dash means the briefing did not search this drug in that disease (it searches the drugs Open Targets lists against its own genes), which is not the same as none. Salt forms, biosimilar suffixes and formulation words are merged by the same rule the briefings use.